If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
156
results.
Updated on
05/06/2025 [07:01:00]
Absstract of: AU2023312740A1
Systems, devices and methods are provided for incorporating a medication delivery device into an integrated management system. The integrated management system may be an integrated diabetes management system and may include a glucose monitor, a connected insulin pen, and software. The integrated management system may produce a plurality of reports that may include data related to analyte levels (e.g., glucose levels) and medication delivered (e.g., insulin delivered). The medication delivery device may also provide feedback to the user.
Absstract of: WO2025109398A1
Non-enzymatic electrochemical glucose sensor (100), for the detection of glucose in biological fluids, characterized in comprising: - a support (101), having a first surface and a second surface opposite to the first surface; - a first metallic electrode (102a), a second metallic electrode (102b), and a third metallic electrode (102c) deposited on said support (101); - a sensitive element consisting of a compound, having a nanoporous structure, deposited on a surface of the second metallic electrode (102b). The invention is also related to a fabrication process of the non-enzymatic electrochemical glucose sensor (100).
Absstract of: US2025172566A1
The present invention relates to saccharide sensing systems including macrocyclic compounds which are capable of binding to a target saccharide (e.g. glucose) and a detectable reporter for providing a detectable signal based on the binding of the target saccharide by the macrocyclic compound.
Absstract of: US2025172539A1
Techniques for data processing and control for a glucose monitoring system are provided, including obtaining a first sensitivity of a glucose sensor; obtaining a second sensitivity of the glucose sensor; comparing a difference between the first sensitivity and the second sensitivity to a predetermined range of values; if the difference is outside the predetermined range of the values, causing a calibration routine for the glucose sensor to be performed; and if the difference is within the predetermined range of values determining a composite sensitivity for a current calibration of the glucose sensor based on the first sensitivity and the second sensitivity and calculating the glucose level based on the current calibration of the glucose sensor.
Absstract of: AU2025203318A1
Systems, devices, and methods are disclosed for wireless communication of analyte data. In embodiments, a method of using a diabetes management partner interface to configure an analyte sensor system for wireless communication with a plurality of partner devices is provided. The method includes the analyte sensor system receiving authorization to provide one of the partner devices with access to a set of configuration parameters via the diabetes management partner interface. The set of configuration parameters is stored in a memory of the analyte sensor system. The method also includes, responsive to input received from the one partner device via the diabetes management partner interface, the analyte sensor system setting or causing a modification to the set of configuration parameters, according to a system requirement of the one partner device.
Absstract of: AU2025203317A1
Systems, devices, and methods are disclosed for wireless communication of analyte data. One such method includes, during a first interval, establishing a first connection between an analyte sensor system and a display device. During the first connection, the method includes exchanging information related to authentication between the analyte sensor system and the display device. The method includes making a determination regarding whether authentication was performed during the first interval. During a second interval, the method may include establishing a second connection between the analyte sensor system and the display device for transmission of an encrypted analyte value, and bypassing the exchanging of information related to authentication performed during the first connection. The method also includes, during the second interval, the analyte sensor system transmitting the encrypted analyte value to the display device, if the determination indicates that the authentication was performed during the first interval.
Absstract of: US2025169728A1
The present disclosure describes lactate-responsive sensors, sensing systems incorporating a lactate-responsive sensor, and methods of use thereof that would be beneficial for continuously monitoring lactate levels and determining lactate thresholds (both aerobic and anaerobic thresholds). The present disclosure also relates to an analyte sensor for continuously detecting glucose and lactate levels.
Absstract of: US2025170330A1
Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.
Absstract of: US2025169764A1
Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a “retrofitting” algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting al
Absstract of: US2025169721A1
A notification device is provided for presenting blood glucose level information for a tracked individual. The notification device is configured to receive first and second blood glucose level information from first and second tracking devices associated with different manufacturers. The first and second blood glucose level information each include at least one of a blood glucose level or a first or second derivative for the blood glucose level as a function of time. The notification device comprises a screen, processor(s), and memory device(s) containing computer readable code. When executed by the processor(s), the computer readable code is configured to cause the processor(s) to receive the first and/or the second blood glucose level information and cause presentation of the first and/or the second blood glucose level information on the screen. The first and second tracking devices are each a continuous blood glucose monitor.
Absstract of: US2025169720A1
A biological test system has receptacles for a variety of removable electro-mechanical biological blood test-based elements having multiple features such as lancets or strips. Testing is through an analysis biological test processor that provides results to a user test output with all designed to be contained in a pocket-transportable user biological test form factor that houses all elements. Biological test elements can be interchanged for multiple sensing modalities with automatic activation based on cartridge insertion of a glucose test element, an A1C test element, a ketone test element, or the like. Designs can include a user sampler configuration selector for a user sampling selection that may be analyzed so a user-personalizable, biological sampler control processor can automatically disable operation for test safety if a user sampling selection is determined to be unacceptable. The system can also provide a user cartridge action prompt, a user reselection prompt, or other action to clear the disable.
Absstract of: US2025174328A1
A system for prescribing insulin doses is provided, wherein a first titration application component structured to is implemented on a patient computing device of the patient, wherein the first titration application component logs glucose level data measured from the patient and insulin dose data indicative of a number of insulin doses given to the patient. The system includes a provider computing including a second titration application component, wherein the second titration application component is structured and configured to receive the glucose level data and the insulin dose data from the patient computing device, determine a correction factor based on a sensitivity constant specified by the healthcare provider, and determine the insulin dose recommendation for the patient based on the insulin dose data, the glucose level data and the correction factor, wherein the provider computing device is structured and configured to transmit the insulin dose recommendation to the patient computing device.
Absstract of: US2025169769A1
A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.
Absstract of: AU2025203433A1
Personalized treatment tool Abstract The present invention relates to a computer-implemented method for aiding in the guidance of diabetes drug therapy of an individual suffering from diabetes mellitus. The method is based on glucose data from said individual that are received at a processing unit, wherein said glucose data comprise at least three fasting glucose measurement values from said in 10 dividual, and/or at least three matched pre-prandial glucose measurement values and post prandial glucose measurement values at the same meal from said individual. Further con templated by the present invention is a device for aiding in the guidance of drug diabetes therapy of an individual suffering from diabetes, said device comprising a processing unit, and a computer program including computer-executable instructions, wherein said instruc 15 tions, when executed by the processing unit, causes the processing unit to perform the com puter-implemented method of the present invention.
Absstract of: WO2025106990A1
Integrated patch-pump devices to deliver drugs, e.g., macromolecular drugs that are difficult to deliver through an oral pathway and/or that require transdermal delivery. Embodiments are slim, powerless, painless, and relatively inexpensive. The microfluidic pump is used to drive the fluid flow powered by pressurized air or the user's pulse, and the microneedle array is used to inject the fluid through the skin painlessly. The flow rate generally positively correlates with the actuation pressure. For devices with wider flow channels, the flow rate generally negatively correlates with the actuation frequency, whereas the flow rate increases and then decreases with increasing actuation frequency for devices with narrower flow channels. This property of these devices is beneficial in insulin delivery because the demand for insulin is generally reduced in vigorous exercise (with elevated heart rate/ actuation frequency) and is increased in hypertension patients (with elevated blood/actuation pressure).
Absstract of: WO2025104963A1
This blood sugar level measuring device comprises: a light output unit that includes a green light source that outputs incident light; a light detection unit that detects transmitted light that has passed through a living body; and a computation unit that calculates the blood sugar level of the living body. In the spectrum of the incident light, the center wavelength is located at 430-580 nm, the intensity at 600-615 nm is at least 0.01% of the intensity at the center wavelength, and the intensity at 480-515 nm is at least 1% of the intensity at the center wavelength. The light detection unit includes a first light detector having a first detection wavelength range of 460-535 nm and a second light detector having a second detection wavelength range of at least 580 nm. The computation unit calculates the blood sugar level of the living body on the basis of the intensity of the transmitted light detected by the first light detector and the intensity of the transmitted light detected by the second light detector.
Absstract of: WO2025102900A1
A non-invasive blood glucose measurement system (100), comprising an optical transceiver assembly (110); a filtering unit (120), electrically connected to the optical transceiver assembly (110); and a micro-processing unit (130), electrically connected to the filtering unit (120). The optical transceiver assembly (110) comprises: at least two light sources (111), a first detector (112) and at least two second detectors (113), the at least two light sources (111) being used for emitting laser detection signals, and the first detector (112) and the at least two second detectors (113) being used for detecting returned laser signals. The at least two light sources (111) are provided around the first detector (112); the at least two second detectors (113) are provided around the light source (111); and a light detection surface of the first detector (112), light detection surfaces of the at least two second detectors (113), and light emergent surfaces of the at least two light sources (111) face the same direction. Data analysis and processing of short-path optical signals and long-path optical signals can obtain an optical concentration difference between a dark portion and a light portion of skin, thereby reducing the influences caused by melanin and skin, and improving the accuracy in non-invasive blood glucose measurement.
Absstract of: WO2025102532A1
Provided is an insulin pen needle rear end protection device, which comprises: a housing (1), wherein the tail end of the housing (1) is arranged to be connected with an insulin injection pen; a needle holder (2) fixed in the housing (1), wherein an injection needle extending to the tail end of the housing (1) is arranged on the needle holder (2), a guide groove (22) is formed in the side wall of the needle holder (2), and a protruding block (23) is further arranged on the inner surface of the side wall of the needle holder (2); and a rear needle protective sleeve (3) arranged in the needle holder (2) in a penetrating manner, wherein a spring (4) is clamped between the rear needle protective sleeve (3) and the needle holder (2), and a positioning column (31) and an elastic clamping jaw (32) are arranged on the outer surface of the rear needle protective sleeve (3). When the insulin pen needle is connected to the injection pen, the rear needle protective sleeve (3) is compressed into the needle holder (2), the positioning column (31) moves in the guide groove (22) to a first position, and the elastic clamping jaw (32) is located on the side of the protruding block (23) away from the tail end of the needle holder (2); when the insulin pen needle is separated from the injection pen, the positioning column (31) moves to a second position along the guide groove (22) under the acting force of the spring (4), such that the rear needle protective sleeve (3) pops up, and the elastic c
Absstract of: WO2025102531A1
A protection device for the front end of an insulin pen needle, comprising: a housing (1); a needle hub (2), which is fixed in the housing (1), the needle hub (2) being provided with an injection needle extending out of the head end of the housing (1); a sliding fastener (3), which is sleeved on the needle hub (2) and is in sliding fit with the needle hub (2), the outer surface of the sliding fastener (3) being provided with a snap-fit portion (31); and a needle tip protective sleeve (4), which is slidably provided in the housing (1), an elastic piece (41) being provided on single side of the inner wall of the needle tip protective sleeve (4), and a spring (5) is clamped between the needle tip protective sleeve (4) and the needle hub (2). When the insulin pen needle is in an injection state, the needle tip protective sleeve (4) presses the spring (5) to retract into the housing (1), such that the needle tip protective sleeve (4) is sleeved on the sliding fastener (3), and in the case that the elastic piece (41) slides to the position of the snap-fit portion (31), the elastic piece (41) hooks the snap-fit portion (31), so as to expose the needle tip of the injection needle (21). When the insulin pen needle is in a retraction state, the needle tip protective sleeve (4) extends out of the housing (1) under the elastic force of the spring (5) and drives the sliding fastener (3) to withdraw from the needle hub (2); the sliding fastener (3) is offset with the needle hub (2) under t
Absstract of: AU2025203154A1
Abstract: Compositions and methods are described for the delivery of a fully human post- translationally modified (HuPTM) monoclonal antibody ("mAb") or the antigen-binding fragment of a mAb against human vascular endothelial growth factor ("hVEGF") - such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment - to the retina/vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration ("nAMD"), also known as "wet" age-related macular degeneration ("WAMD"), age-related macular degeneration ("AMD"), and diabetic retinopathy.
Absstract of: WO2025102533A1
An insulin pen needle front-end protection apparatus, comprising a housing (1), the housing(1) being provided with a first through hole (11) in a head end; a needle base (2) fixedly connected to a tail end of the housing (1), the needle base (2) being provided with a protruding portion (21) extending towards the head end of the housing (1), and an injection needle (22) extending out of the first through hole (11) being arranged on the protruding portion (21); a sliding buckle (3) sleeved on the protruding portion (21), a constriction structure being arranged at a tail end of the sliding buckle (3), and a head end of the sliding buckle (3) being provided with a second through hole (31); and a needle tip protection sleeve (4) at least partially arranged in the housing (1), a spring (5) being clamped between a tail end of the needle tip protection sleeve (4) and the needle base (2), a head end of the needle tip protection sleeve (4) extending out of the first through hole (11) and being provided with a third through hole (41), and at least two clamping buckles (42) being arranged on an inner wall of the needle tip protection sleeve (4).
Absstract of: US2025160749A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: US2025160748A1
The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.
Absstract of: US2025160703A1
A system for reducing sensor variability includes a sensor configured to generate real-time data relating to glucose sensitivity. The system causes performance of accessing the real-time data from the sensor relating to glucose sensitivity and inputting the real-time data into a machine learning model. The system also causes performance of estimating by the machine learning model an expected glucose sensitivity based on the real-time data and correcting the glucose sensitivity based on the expected glucose sensitivity.
Nº publicación: AU2025203062A1 22/05/2025
Applicant:
INSULET CORP
INSULET CORPORATION
Absstract of: AU2025203062A1
The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).
BOPI
Electronic site
